Literature DB >> 11409721

Co-localization of 5-HT(1B/1D/1F) receptors and glutamate in trigeminal ganglia in rats.

Q P Ma1.   

Abstract

Anti-migraine triptan drugs are 5-HT(1B/1D) receptor agonists which are thought to block the neurotransmitter/neuropeptide release from sensory nerve terminals and directly constrict blood vessel smooth muscles. In the present study, we have investigated the anatomical basis for a possible modulation of glutamate release from trigeminal ganglion neurons by 5-HT(1B/1D) receptor agonists and by 5-HT1F receptor agonists, using double immunohistochemical staining technique in the rat. The majority of 5-HT1B, 5-HT1D or 5-HT1F receptor positive neurons were also glutamate positive, but both 5-HT1B, 5-HT1D or 5-HT1F receptor single-labeled and glutamate single-labeled neurons were observed. These results suggest that 5-HT(1B/1D/1F) receptor agonists may modulate glutamate release, and that one mechanism of their anti-migraine action could be the blockade of glutamate release.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11409721     DOI： 10.1097/00001756-200106130-00015

Source DB:  PubMed          Journal:  Neuroreport        ISSN： 0959-4965            Impact factor:   1.837


  24 in total

Review 1.  Chemical mediators of migraine: preclinical and clinical observations.

Authors:  Saurabh Gupta; Stephanie J Nahas; B Lee Peterlin
Journal:  Headache       Date:  2011-06       Impact factor: 5.887

2.  Nitric oxide regulation of calcitonin gene-related peptide gene expression in rat trigeminal ganglia neurons.

Authors:  Jamie Bellamy; Elizabeth J Bowen; Andrew F Russo; Paul L Durham
Journal:  Eur J Neurosci       Date:  2006-04       Impact factor: 3.386

Review 3.  5-HT(1F) Receptor agonists: a new treatment option for migraine attacks?

Authors:  Lars Neeb; Jannis Meents; Uwe Reuter
Journal:  Neurotherapeutics       Date:  2010-04       Impact factor: 7.620

4.  New targets for migraine therapy.

Authors:  Amy R Tso; Peter J Goadsby
Journal:  Curr Treat Options Neurol       Date:  2014-11       Impact factor: 3.598

5.  Glutamate levels and perfusion in pons during migraine attacks: A 3T MRI study using proton spectroscopy and arterial spin labeling.

Authors:  Samaira Younis; Casper E Christensen; Mark B Vestergaard; Ulrich Lindberg; Daniel Tolnai; Olaf B Paulson; Henrik Bw Larsson; Anders Hougaard; Messoud Ashina
Journal:  J Cereb Blood Flow Metab       Date:  2020-05-19       Impact factor: 6.200

Review 6.  Glutamate and Its Receptors as Therapeutic Targets for Migraine.

Authors:  Jan Hoffmann; Andrew Charles
Journal:  Neurotherapeutics       Date:  2018-04       Impact factor: 7.620

7.  Migraine: an overview.

Authors:  Salvatore Salomone; Filippo Caraci; Anna Capasso
Journal:  Open Neurol J       Date:  2009-10-01

Review 8.  Current and prospective pharmacological targets in relation to antimigraine action.

Authors:  Suneet Mehrotra; Saurabh Gupta; Kayi Y Chan; Carlos M Villalón; David Centurión; Pramod R Saxena; Antoinette MaassenVanDenBrink
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-07-15       Impact factor: 3.000

9.  Serotonin as a modulator of glutamate- and GABA-mediated neurotransmission: implications in physiological functions and in pathology.

Authors:  L Ciranna
Journal:  Curr Neuropharmacol       Date:  2006-04       Impact factor: 7.363

10.  Disruption of communication between peripheral and central trigeminovascular neurons mediates the antimigraine action of 5HT 1B/1D receptor agonists.

Authors:  Dan Levy; Moshe Jakubowski; Rami Burstein
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-11       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.